PhoreMost Announces Lead Oncology Programme and Appoints Chief Medical Officer to Support Clinical Entry
PhoreMost Limited (“PhoreMost”), a biotech company focused on turning scientific breakthroughs into life-changing cancer drugs, today announced its lead programme, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers. The milestone marks the Company’s progress towards first-in-human clinical trials, with a pipeline of differentiated and first-in-class assets in oncology.
